Physician profile
Donald E Jones
NPI 1811988108
$5,144.21
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,378 · 2020: $258 · 2021: $629 · 2022: $1,264 · 2023: $889 · 2024: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,481.66 | 2019-2024 | Senza |
| Mml US, INC. | $404.43 | 2022-2023 | Reactiv8 |
| Medtronic USA, INC. | $335.85 | 2019 | |
| Abbott Laboratories | $321.68 | 2019-2024 | Proclaim, Eterna |
| Amgen INC. | $228.15 | 2019-2023 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $224.79 | 2019-2020 | |
| Lilly USA, LLC | $212.07 | 2019-2023 | Emgality, Reyvow |
| Lundbeck LLC | $187.21 | 2022-2024 | Vyepti |
| Tersera Therapeutics LLC | $146.71 | 2023-2024 | Prialt |
| Abbvie INC. | $141.23 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $141.05 | 2019-2024 | Ztlido |
| Collegium Pharmaceutical, INC. | $127.09 | 2023-2024 | Belbuca, Xtampza |
| Curonix LLC | $118.75 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nalu Medical, INC. | $112.45 | 2021-2024 | Nalu Neurostimulation System |
| Stimwave Technologies Incorporated | $108.79 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.